心脏衰竭与减少的喷射部分:医疗管理
Robert L Gauer1, Adam Rifaat1, Ashley M Foulkrod1
1Womack Army Medical Center, Fort Bragg, North Carolina.
American family physician
|August 20, 2025
概括
包括四个关键药物类别在内的指导药物治疗改善了心力衰竭患者的存活率和生活质量. 调整和二次治疗对于持续的症状和管理副作用至关重要.
科学领域:
- 心脏病学
- 药理学
- 医学治疗
背景情况:
- 治疗心力衰竭减排分数 (HFrEF) 的进展,导致患者的存活时间增加.
- 目前的治疗旨在减少死亡率,住院和症状,同时提高功能状态和生活质量.
研究的目的:
- 概述目前针对HFrEF的指导医学治疗 (GDMT).
- 讨论二次疗法,副作用的管理以及铁替代和器械疗法的作用.
主要方法:
- 对HFrEF的既定和新兴治疗方法的审查.
- 强调指导方针推的药理干预措施.
- 包括设备治疗和诊断工具,如护理点超声波.
主要成果:
- 已证实GDMT,包括雷宁- 血管素系统/ 尼普利辛抑制剂,β抑制剂,矿物质皮质体受体对抗剂和SGLT-2抑制剂,可降低发病率和死亡率.
- 在特定的患者群体中,二次疗法和静脉铁替代疗法改善了结果.
- 设备治疗解决心脏突然死亡风险,超声波帮助诊断和治疗评估.
结论:
- 综合管理HFrEF包括及时启动和定位GDMT.
- 个性化治疗策略,包括二次疗法和支持性干预措施,对于优化患者的治疗结果至关重要.
- 持续监测和调整治疗对于治疗不良反应和改善HFrEF患者的生活质量至关重要.
相关概念视频
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Mitral Regurgitation III: Medical Management
30
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
30
Rheumatic Heart Disease III: Medical Management
32
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
32


